Roswell Park Comprehensive Cancer Center

Roswell Park Team Members Recognized for Exceptional Support to First Responders

November 19th 2024

Nurse-executive and partnership manager honored for dedication to local heroes.

New Computational Method Links One Mammal’s Striking Longevity and Resistance to Cancer With ‘Dark Genome’

October 30th 2024

A Roswell Park study reveals the evolutionary stability of the naked mole-rat’s genome, and implications for drug development.

Roswell Park Radiation Oncologist Highlights New Insights on Single-Fraction Radiation for Central Lung Tumors

October 16th 2024

Study featured at ASTRO 2024 is one of the first to assess single-fraction SBRT for centrally located lung cancers

Study Highlights Promising New Treatment Option for Patients With Treatment-Resistant Acute Myeloid Leukemia

October 11th 2024

Roswell Park’s Dr. Eunice Wang led KOMET-001 clinical trial; results newly reported in The Lancet Oncology.

Roswell Park–Designed Treatment Regimen Doubles Progression-Free Survival in Metastatic Kidney Cancer

October 1st 2024

Disparities Narrowing Among Patients Undergoing Blood Stem Cell Transplant, Roswell Park Study Reveals

September 24th 2024

Black patients and older adults are least likely to undergo this treatment for blood cancers and hematologic disorders.

Roswell Park Again Named a Top 10 New York State Employer by Forbes

August 30th 2024

Third year in a row cancer center has been ranked on this listing, based on employee surveys.

Final Results of Phase 2 Clinical Trial Clarify Role of JAK2 Inhibitor in Combating Acute Graft-Versus-Host Disease

August 23rd 2024

A study demonstrates that adding a JAK2 inhibitor to standard immunosuppressive drugs does not improve prevention of acute graft-versus-host disease.

Daily Use of E-Cigarettes Linked to Higher Cigarette Quit Rates, Roswell Park Research Shows

August 14th 2024

A study led by experts at Roswell Park Comprehensive Cancer Center suggests that e-cigarette use may help some people quit using combustible cigarettes. 

Roswell Park Insights on Role of Exportin 1 Protein Suggest Strategy for Improving Cancer Immunotherapy

July 11th 2024

Research team shares new data on how XPO1 blockade may boost immune-based treatments.

New Study from Roswell Park Pinpoints Cells That May Drive Treatment Resistance in Prostate Cancer

July 8th 2024

Using multiomics, the team identifies novel therapeutic targets in castration-resistant prostate cancer.

Roswell Park Earns ‘Exceptional’ Rating from National Cancer Institute With Best-Ever Core Grant

July 4th 2024

Roswell Park Comprehensive Cancer Center earns maximum rating, marking five decades of consecutive NCI support.

Roswell Park-Led Research Shows Muscle & Fat Strongly Linked to Survival in Epithelial Ovarian Cancer

June 16th 2024

Roswell Park researchers and partners shed light on how body composition at the time of diagnosis relates to mortality in epithelial ovarian cancer.

Roswell Park Experts Launch Comprehensive Lung Cancer Screening List for New York State

June 10th 2024

To improve access to lung cancer screening, Roswell Park Comprehensive Cancer Center experts have launched an online provider registry.

Study Shows Polygenic Risk Score (PGS) Could Predict Breast Cancer Survival Outcomes

June 8th 2024

Data from a large prospective cohort study reveal that a polygenic risk score has the potential to predict survival outcomes in patients with breast cancer. 

Roswell Park Thoracic Chair Tapped as Chief Strategy Officer, Senior VP of Business Development & Outreach

June 4th 2024

Sai Yendamuri, MD, MBA, FACS, has been appointed as Chief Strategy Officer and Senior Vice President of Business Development and Outreach.

Roswell Park Again Named an ‘LGBTQ+ Healthcare Equality Leader’

May 23rd 2024

Roswell Park Comprehensive Cancer Center earned top score of 100 on Human Rights Campaign Foundation survey.

Pediatric Multicenter Study Shows Targeted Therapy for High-Risk Hodgkin Lymphoma Reduces Relapse

November 8th 2022

A targeted therapy for children with high-risk Hodgkin lymphoma was shown to significantly reduce relapse rates when tested in a clinical trial conducted by the Children’s Oncology Group and led by pediatric oncologists at Roswell Park Comprehensive Cancer Center, Children’s Healthcare of Atlanta and Winship Cancer Institute of Emory University.